Loading...
•
Dec 31, 2019
Matinas BioPharma Q4 2019 Earnings Report
Reported fourth quarter and full year 2019 financial results and operational highlights.
Key Takeaways
Matinas BioPharma reported a net loss attributable to common shareholders of $5.8 million for the fourth quarter of 2019. The company's cash, cash equivalents and marketable securities were approximately $27.8 million as of December 31, 2019. They initiated the ENHANCE-IT study of MAT9001 against Vascepa and the efficacy phase of the NIH-funded EnACT study of MAT2203.
Initiated ENHANCE-IT study of MAT9001 against Vascepa, with topline data expected in Q4 2020.
Initiated efficacy phase of NIH-funded EnACT study of MAT2203 in cryptococcal meningitis in Q1 2020.
Cash, cash equivalents and marketable securities were approximately $27.8 million at December 31, 2019.
Net loss attributable to common shareholders was $5.8 million, or a net loss per share of $0.04 for the fourth quarter of 2019.
Matinas BioPharma
Matinas BioPharma
Forward Guidance
Matinas BioPharma believes that cash on hand is sufficient to fund operations into the second half of 2022.